Holly K. Tabor, PhD and Aaron Goldenberg, PhD, MPH
Rare genetic disease research has something to teach precision medicine about addressing some patients’ limited access to treatment. Health disparities exacerbated by high costs and limited availability of drugs can, perhaps, be mitigated when patient activism accelerates drug development.
AMA J Ethics. 2018;20(9):E834-840. doi:
10.1001/amajethics.2018.834.
Rebekah Davis Reed, PhD, JD and Erik L. Antonsen, PhD, MD
Though the National Aeronautics and Space Administration’s collection of disaggregated genetic data for occupational surveillance and research raises numerous privacy concerns, the Genetic Information Nondiscrimination Act of 2008 allows genetic information to be used to develop personal pharmaceuticals.
AMA J Ethics. 2018;20(9):E849-856. doi:
10.1001/amajethics.2018.849.
Pathologists should work cooperatively with clinicians and provide guidance about appropriate testing to uphold the medical ethics principle of justice.
AMA J Ethics. 2016;18(8):793-799. doi:
10.1001/journalofethics.2016.18.8.ecas5-1608.
Cytopathologists frequently interact directly with patients at their bedsides to perform fine needle aspiration procedures. When, if ever, should cytopathologists share preliminary diagnostic impressions directly with patients?
AMA J Ethics. 2016;18(8):779-785. doi:
10.1001/journalofethics.2016.18.8.ecas3-1608.
Dr David Marcus joins Ethics Talk to discuss his article: “When, If Ever, Is It Appropriate to Regard a Patient as ‘Too Medically Complex’ for One Inpatient Service, But Not Another?”
Dr Emma Cooke joins Ethics Talk to discuss her article, coauthored with Dr Holland Kaplan: “How Should Technology-Dependent Patients’ Care Be Managed Collaboratively to Avoid Turfing?”
Using data from comparative effectiveness studies to inform cost-effectiveness analyses or other economic evaluations would strengthen ethical policy making.
AMA J Ethics. 2015;17(7):651-655. doi:
10.1001/journalofethics.2015.17.7.pfor1-1507.